Results 171 to 180 of about 118,208 (200)
Some of the next articles are maybe not open access.
HPLC analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids
Journal of Pharmaceutical and Biomedical Analysis, 1995An improved high-performance liquid chromatography (HPLC) procedure for the analysis of ciprofloxacin and three of its metabolites in plasma, serum and urine samples was developed. The previously published HPLC procedure described the isocratic separation of ciprofloxacin and three ciprofloxacin metabolites in urine samples on a polystyrene ...
G.W. Beck, T. Benham, G.J. Krol
openaire +2 more sources
Anaphylactoid Reaction to Ciprofloxacin
Annals of Pharmacotherapy, 2003OBJECTIVE: To report a case of anaphylactoid reaction in an HIV-negative patient associated with the administration of intravenous ciprofloxacin. CASE SUMMARY: A 79-year-old Armenian man developed an anaphylactoid reaction following a first-time exposure to intravenous ciprofloxacin.
Clifford C. Wang +2 more
openaire +3 more sources
Ciprofloxacin and salmonella carriage
Journal of Hospital Infection, 1992Infection with non-typhoidal Salmonella spp. continues to be a major cause of diarrhoeal illness in the UK with more than 25 000 cases reported in England and Wales in 1990. These infections are associated with convalescent faecal carriage of salmonellae for a mean of 4 weeks (longer in young children’) and, in less than 1% of individuals, with chronic
D. Nathwani, M.J. Wood
openaire +3 more sources
Clinical Pharmacokinetics of Ciprofloxacin
Clinical Pharmacokinetics, 1990Compared with nalidixic acid, ciprofloxacin is representative of a newer, more potent class of quinolones, termed the fluoroquinolones. It is available in both oral and parenteral dosage forms. The primary target of quinolone activity appears to be the bacterial DNA gyrase enzyme, which is a member of the class of type II topoisomerases.
John C. Rotschafer +2 more
openaire +2 more sources
Ciprofloxacin in combination with metronidazole
Infection, 1988Ciprofloxacin has a reduced activity against anaerobic pathogens. Therefore, a combination of ciprofloxacin with an antimicrobial agent active against anaerobes, such as metronidazole, seems to be interesting for the treatment of mixed aerobic/anaerobic infections. High metronidazole concentrations (10 mg/l or 40 mg/l) neither affected the bactericidal
R. Werk, L. Schneider
openaire +3 more sources
Annals of Internal Medicine, 1989
Excerpt The recent letter by Linville and Matanin (1) brought attention to an interaction between norfloxacin (Noroxin, Merck Sharp & Dohme, West Point, Pennsylvania) and warfarin that resulted in ...
Sean M. Murphy +2 more
openaire +2 more sources
Excerpt The recent letter by Linville and Matanin (1) brought attention to an interaction between norfloxacin (Noroxin, Merck Sharp & Dohme, West Point, Pennsylvania) and warfarin that resulted in ...
Sean M. Murphy +2 more
openaire +2 more sources
Metabolic interactions of ciprofloxacin
Diagnostic Microbiology and Infectious Disease, 1990The mechanism and clinical relevance of the inhibitory effect of ciprofloxacin on the metabolism of selected drugs were studied in patients with bacterial infections. In study A, antipyrine tests were carried out in two groups of patients taking 1000 mg (group 1) and 250 mg (group 2) of oral ciprofloxacin for 7-10 days.
András Csiba +3 more
openaire +2 more sources
Ciprofloxacin for treatment of malakoplakia
The Lancet, 1992The tumour-like lesions of the rare disease malakoplakia, which consist of macrophages containing undigested coliform bacteria, are often misdiagnosed as a carcinoma. Although an infectious aetiology is likely, no antimicrobial therapy has been successful in the long-term. Since ciprofloxacin penetrates well into macrophages, this drug was given to two
P.A. Wertheimer +3 more
openaire +2 more sources